DRKS00019080已完成不适用
eurological immune-related adverse events in checkpoint Inhibitor therapy
niversitätsklinikum Essen0 个研究点目标入组 66 人开始时间: 2019年11月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •1. patient's consent
- •2. Age above 18 years
- •3. sufficient knowledge of German language
- •4. diagnosis of metastatic melanoma
- •5. checkpoint Inhibitor therapy
排除标准
- •1. restricted legal capacity
研究者
相似试验
已完成
不适用
Registry Study of Immune-Related Adverse Events using ePRO in Cancer Patients Receiving Immune Checkpoint Inhibitorsung cancer,Malignant pleural mesothelioma,Gastrointestinal cancerJPRN-UMIN000046418MHLW(Japan)260
招募中
不适用
Analysis of immune-related adverse event by immune checkpoint inhibitorpatients treated by immune checkpoint inhibitorJPRN-UMIN000031806Chiba University180
已完成
不适用
Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung CancerCarcinoma, Non-Small-Cell LungDrug-Related Side Effects and Adverse ReactionsNCT03125603Cliniques universitaires Saint-Luc- Université Catholique de Louvain80
招募中
不适用
Immune Related Rheumatological Adverse Events. Data collection from patients with cancer to evaluate rheumatological adverse events in patients treated with immune-checkpoint inhibitors.Rheumatological side effects to therapy1000381610027655NL-OMON54205Vrije Universiteit Medisch Centrum495
进行中（未招募）
1 期
A study of safety, effect on the immune system and blood clotting of BAX855 (factor VIII of blood clotting) in pediatric patients who have not received or received minimal treatment for their severe hemophilia A.EUCTR2015-002136-40-ITBAXALTA INNOVATIONS GMBH120